19:30 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Alnylam, Sanofi start Phase III program of fitusiran for hemophilia

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) began the open-label, international Phase III ATLAS program of fitusiran (ALN-AT3, SAR439774) to treat hemophilia A and B. Top-line data are expected...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: E. coli exopolyphosphatase (PPX)

Cardiovascular disease INDICATION: Thrombosis Human plasma, human blood and mouse studies suggest E. coli PPX could help treat thrombosis. In human and mouse platelet-rich plasma-based clotting assays, E. coli PPX decreased coagulation and increased time...
08:00 , Dec 19, 2005 |  BC Week In Review  |  Clinical News

PRX302: IND submitted

PPX submitted an IND to begin an open-label, dose-escalation, U.S. Phase I trial in 18 to 24 patients. Protox Therapeutics Inc. (TSX-V:PRX), Vancouver, B.C.   Product: PRX302   Business: Cancer   Molecular target: Not available...